# Exome Asset Management LLC 13F Q2 2026: $162 million

Exome Asset Management LLC reported $162 million in 13F securities across 52 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Guardant Health Inc at $10.1 million, 6.2% of the reported value. Since Q1 2026 it opened 15 new positions and exited 19.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $162,102,170
- Positions: 52
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 2011932
- Form 13F file number: 028-23951
- CRD number: 304585
- Business address: 330 Madison Avenue, New York, NY 10017
- SEC filing: [0001420506-26-001714](https://www.sec.gov/Archives/edgar/data/2011932/000142050626001714/0001420506-26-001714-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/exome-asset-management-llc-304585)

## Top 25 holdings by value

The largest of 52 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Guardant Health Inc](https://specstream.ai/data/institutional-holders/guardant-health-inc-40131m109) | COM | 67,500 | $10.1 million | -15,236 |
| [Praxis Precision Medicines I](https://specstream.ai/data/institutional-holders/praxis-precision-medicines-i-74006w207) | COM NEW | 27,205 | $9.1 million | -18,264 |
| [TG Therapeutics Inc](https://specstream.ai/data/institutional-holders/tg-therapeutics-inc-88322q108) | COM | 164,915 | $9.1 million | New |
| [Cogent Biosciences Inc](https://specstream.ai/data/institutional-holders/cogent-biosciences-inc-19240q201) | COM | 210,523 | $8.1 million | -68,010 |
| [Ionis Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/ionis-pharmaceuticals-inc-462222100) | COM | 88,177 | $7 million | -21,887 |
| [Eli Lilly & Co](https://specstream.ai/data/institutional-holders/eli-lilly-co-532457108) | COM | 5,492 | $6.6 million | -1,520 |
| [Abivax SA](https://specstream.ai/data/institutional-holders/abivax-sa-00370m103) | SPONSORED ADS | 46,878 | $6.2 million | New |
| [Alumis Inc](https://specstream.ai/data/institutional-holders/alumis-inc-022307102) | COM | 204,418 | $5.8 million | -74,758 |
| [Cytokinetics Inc](https://specstream.ai/data/institutional-holders/cytokinetics-inc-23282w605) | COM NEW | 60,056 | $5.1 million | -43,662 |
| [Enliven Therapeutics Inc](https://specstream.ai/data/institutional-holders/enliven-therapeutics-inc-29337e102) | COM | 100,203 | $5.1 million | -119,888 |
| [Vera Therapeutics Inc](https://specstream.ai/data/institutional-holders/vera-therapeutics-inc-92337r101) | CL A | 97,276 | $4.2 million | -17,715 |
| [Unitedhealth Group Inc](https://specstream.ai/data/institutional-holders/unitedhealth-group-inc-91324p102) | COM | 9,612 | $4 million | -3,250 |
| [10x Genomics Inc](https://specstream.ai/data/institutional-holders/10x-genomics-inc-88025u109) | CL A COM | 102,629 | $3.9 million | -51,565 |
| [Natera Inc](https://specstream.ai/data/institutional-holders/natera-inc-632307104) | COM | 13,800 | $3.7 million | -4,850 |
| [Uniqure NV](https://specstream.ai/data/institutional-holders/uniqure-nv-n90064101) | SHS | 81,056 | $3.7 million | New |
| [Rhythm Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/rhythm-pharmaceuticals-inc-76243j105) | COM | 32,209 | $3.6 million | -8,372 |
| [Maze Therapeutics Inc](https://specstream.ai/data/institutional-holders/maze-therapeutics-inc-578784100) | COM | 114,692 | $3.4 million | +26,182 |
| [Monte Rosa Therapeutics Inc](https://specstream.ai/data/institutional-holders/monte-rosa-therapeutics-inc-61225m102) | COM | 137,115 | $3.3 million | -42,369 |
| [Moonlake Immunotherapeutics](https://specstream.ai/data/institutional-holders/moonlake-immunotherapeutics-61559x104) | CLASS A ORD | 166,493 | $3.2 million | -48,883 |
| [Alkermes PLC](https://specstream.ai/data/institutional-holders/alkermes-plc-g01767105) | SHS | 61,336 | $3.2 million | -22,767 |
| [Liquidia Corporation](https://specstream.ai/data/institutional-holders/liquidia-corporation-53635d202) | COM NEW | 39,224 | $3.1 million | -6,572 |
| [United Therapeutics Corp Del](https://specstream.ai/data/institutional-holders/united-therapeutics-corp-del-91307c102) | COM | 5,410 | $2.9 million | -1,643 |
| [Glaukos Corp](https://specstream.ai/data/institutional-holders/glaukos-corp-377322102) | COM | 19,862 | $2.8 million | -1,012 |
| [Arrowhead Pharmaceuticals in](https://specstream.ai/data/institutional-holders/arrowhead-pharmaceuticals-in-04280a100) | COM | 32,214 | $2.6 million | -13,507 |
| [Agios Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/agios-pharmaceuticals-inc-00847x104) | COM | 70,500 | $2.6 million | -54,560 |

## New positions in Q2 2026

15 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [TG Therapeutics Inc](https://specstream.ai/data/institutional-holders/tg-therapeutics-inc-88322q108) | COM | 164,915 | $9.1 million |
| [Abivax SA](https://specstream.ai/data/institutional-holders/abivax-sa-00370m103) | SPONSORED ADS | 46,878 | $6.2 million |
| [Uniqure NV](https://specstream.ai/data/institutional-holders/uniqure-nv-n90064101) | SHS | 81,056 | $3.7 million |
| [Astrazeneca PLC](https://specstream.ai/data/institutional-holders/astrazeneca-plc-g0593m107) | ORD | 12,045 | $2.3 million |
| [Viking Therapeutics Inc](https://specstream.ai/data/institutional-holders/viking-therapeutics-inc-92686j106) | COM | 47,861 | $1.9 million |
| [Ocular Therapeutix Inc](https://specstream.ai/data/institutional-holders/ocular-therapeutix-inc-67576a100) | COM | 181,588 | $1.8 million |
| [Equillium Inc](https://specstream.ai/data/institutional-holders/equillium-inc-29446k106) | COM | 552,956 | $1.8 million |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 6,573 | $1.8 million |
| [Nektar Therapeutics](https://specstream.ai/data/institutional-holders/nektar-therapeutics-640268306) | COM NEW | 22,417 | $1.6 million |
| [Clearpoint Neuro Inc](https://specstream.ai/data/institutional-holders/clearpoint-neuro-inc-18507c103) | COM | 83,636 | $1.5 million |
| [Caris Life Sciences Inc](https://specstream.ai/data/institutional-holders/caris-life-sciences-inc-142152107) | COM | 78,180 | $1.4 million |
| [Geron Corp](https://specstream.ai/data/institutional-holders/geron-corp-374163103) | COM | 624,046 | $798,779 |
| [Bright Minds Biosciences Inc](https://specstream.ai/data/institutional-holders/bright-minds-biosciences-inc-10919w405) | COM NEW | 10,110 | $709,722 |
| [Compass Therapeutics Inc](https://specstream.ai/data/institutional-holders/compass-therapeutics-inc-20454b104) | COM | 276,165 | $604,801 |
| [Replimune Group Inc](https://specstream.ai/data/institutional-holders/replimune-group-inc-76029n106) | COM | 40,361 | $446,796 |

## Positions exited in Q2 2026

19 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| SPDR Series Trust | ST STR SP BIOT (put) | 60,000 | $7.7 million |
| [Elevance Health Inc Formerly](https://specstream.ai/data/institutional-holders/elevance-health-inc-formerly-036752103) | COM | 14,677 | $4.3 million |
| Cytokinetics Inc | PUT (put) | 60,000 | $4 million |
| Apellis Pharmaceuticals Inc | COM | 85,517 | $3.4 million |
| Beone Medicines LTD | SPONSORED ADS (call) | 10,000 | $3 million |
| [Avalo Therapeutics Inc](https://specstream.ai/data/institutional-holders/avalo-therapeutics-inc-05338f306) | COM NEW | 159,341 | $2.4 million |
| Alumis Inc | PUT (put) | 105,000 | $2.3 million |
| Soleno Therapeutics Inc | COM | 61,673 | $2.1 million |
| Liquidia Corporation | PUT (put) | 40,000 | $1.5 million |
| Centessa Pharmaceuticals PLC | PUT (put) | 34,700 | $1.4 million |
| Ideaya Biosciences Inc | CALL (put) | 40,000 | $1.3 million |
| Ideaya Biosciences Inc | CALL (call) | 40,000 | $1.3 million |
| [4d Molecular Therapeutics in](https://specstream.ai/data/institutional-holders/4d-molecular-therapeutics-in-35104e100) | COM | 130,564 | $1.2 million |
| [Nextcure Inc](https://specstream.ai/data/institutional-holders/nextcure-inc-65343e207) | COM NEW | 115,500 | $1.2 million |
| [Palisade Bio Inc](https://specstream.ai/data/institutional-holders/palisade-bio-inc-696389402) | COM | 600,000 | $1.1 million |
| Travere Therapeutics Inc | PUT (put) | 20,000 | $594,200 |
| [Lipocine Inc New](https://specstream.ai/data/institutional-holders/lipocine-inc-new-53630x203) | COM NEW | 60,861 | $486,279 |
| Wave Life Sciences LTD | PUT (put) | 30,000 | $217,500 |
| Compass Therapeutics Inc | CALL (call) | 25,100 | $132,779 |

## Also on SpecStream

- [Exome Asset Management LLC Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/2011932/000142050626001714/0001420506-26-001714-index.htm)
- [Exome Asset Management LLC investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/exome-asset-management-llc-304585)
- [Largest 13F filers in New York](https://specstream.ai/data/institutional-holdings/state/new-york)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in New York, New York

- [Handyman services in New York, New York](https://specstream.ai/data/businesses/handyman-services/new-york-new-york-united-states)
- [Turkish restaurants in New York, New York](https://specstream.ai/data/businesses/turkish-restaurants/new-york-new-york-united-states)
- [Hospitals in New York, New York](https://specstream.ai/data/businesses/hospitals/new-york-new-york-united-states)
- [Video production companies in New York, New York](https://specstream.ai/data/businesses/video-production-companies/new-york-new-york-united-states)
- [Importers in New York, New York](https://specstream.ai/data/businesses/importers/new-york-new-york-united-states)
- [Wine bars in New York, New York](https://specstream.ai/data/businesses/wine-bars/new-york-new-york-united-states)
